Arcutis Biotherapeutics
ARQT
ARQT
136 hedge funds and large institutions have $684M invested in Arcutis Biotherapeutics in 2023 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 68 increasing their positions, 28 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
14% less capital invested
Capital invested by funds: $797M → $684M (-$113M)
24% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 29
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Holders
136
Holding in Top 10
2
Calls
$5.06M
Puts
$3.61M
Top Buyers
| 1 | +$19.8M | |
| 2 | +$15.4M | |
| 3 | +$13.2M | |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$7.62M |
| 5 |
PBPIA
Pivotal bioVenture Partners Investment Advisor
San Francisco,
California
|
+$5.11M |
Top Sellers
| 1 | -$17.9M | |
| 2 | -$12.3M | |
| 3 | -$11.6M | |
| 4 |
Barclays
London,
United Kingdom
|
-$10.4M |
| 5 |
MFS
Mirabella Financial Services
London,
United Kingdom
|
-$9.85M |